Dagmar Rosa-Bjorkeson

Dagmar Rosa-Bjorkeson currently works at New Jersey City University Foundation, as Director and Deirdres House, as Director.
Ms. Rosa-Bjorkeson also formerly worked at Intercept Pharmaceuticals, Inc., as Independent Director from 2021 to 2023, Xencor, Inc., as Independent Director from 2019 to 2025, Baxalta, Inc., as President-Biosimilars & EVP from 2014 to 2016, Novartis Pharmaceuticals Corp., as Vice President & Head-Multiple Sclerosis Business from 1997 to 2014, Hoechst Pharmaceuticals Ltd., as Sales Representative, Mallinckrodt Medical, Inc. (US), as Executive VP, Chief Strategy & Development Officer from 2017 to 2020, Novartis Sverige AB, as President, Mallinckrodt Plc, as Chief Strategy & Corporate Development Officer from 2018 to 2020, and Mesoblast Ltd., as Chief Operating Officer from 2020 to 2024.
Ms. Rosa-Bjorkeson received her undergraduate degree, graduate degree, and Masters Business Admin degree from The University of Texas at Austin.